If there was a clinical trial indication at level C or D for a specific cancer type, such as amplification of MDM2 or FGFR1 or mutations of AKT1, ATM, CDK12, and PTEN, patients were considered as candidates for receiving treatment, although in most cases, no clinical trials were available. This evidence concerns the gene FGFR1 and cancer.